Caribou Biosciences, Inc. (CRBU) — Financial statements
Income statement, balance sheet, and cash flow for Caribou Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 11↑11.7% | 10↓71.0% | 34↑148.9% | 14↑44.3% | 10 | |
| Cost of Revenue | 4↓7.2% | 4↑11.4% | 4↓3.2% | 4↑270.0% | 0.98 | |
| Gross Profit | 8↑23.9% | 6↓80.4% | 31↑203.2% | 10↑18.5% | 9 | |
| Operating Expenses | ||||||
| R&D Expenses | 109↓15.9% | 130↑16.1% | 112↑36.3% | 82↑57.4% | 52 | |
| General & Administrative Expenses | 38↓18.4% | 46↑20.8% | 38↑1.2% | 38 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 38↓18.4% | 46↑20.8% | 38↑1.2% | 38↑62.9% | 23 | |
| Other Expenses | -4↑7.2% | -4↓11.4% | -4↑3.2% | -4 | 0.00 | |
| Operating Expenses | 144↓16.8% | 173↑17.5% | 147↑26.1% | 117↑54.3% | 76 | |
| Total Costs & Expenses | 147↓16.6% | 177↑17.3% | 151↑25.2% | 120↑57.0% | 77 | |
| Operating Results | ||||||
| Operating Income | -136↑18.3% | -167↓43.6% | -116↓9.1% | -106↓58.9% | -67 | |
| Depreciation & Amortization | 4↓7.2% | 4↑11.4% | 4↓3.2% | 4↑270.0% | 0.98 | |
| EBITDA | -133↑18.5% | -163↓44.6% | -113↓17.6% | -96↓45.9% | -66 | |
| EBIT | -136↑18.3% | -167↓43.6% | -116↓16.8% | -99↓49.2% | -67 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8 | 0.00↓100.0% | 11↑132.6% | 5↑3185.7% | 0.14 | |
| Interest Income | 8 | 0.00↓100.0% | 11↑132.6% | 5↑3008.1% | 0.15 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -7↓1730.6% | -0.39 | |
| Other Income / Expenses | -12↓171.3% | 18↑23.4% | 14↑101.2% | 7↑1769.5% | 0.38 | |
| Income Before Tax | -149↑0.3% | -149↓46.4% | -102↓2.5% | -99↓49.2% | -67 | |
| Income Tax Expense | -0.55↓6011.1% | -0.01↓104.7% | 0.19↑175.7% | 0.07↓78.2% | 0.32 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -148↑0.7% | -149↓46.1% | -102↓2.7% | -99↓48.6% | -67 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -148↑0.7% | -149↓46.1% | -102↓2.7% | -99↓48.6% | -67 | |
| Bottom-Line Net Income | -148↑0.7% | -149↓46.1% | -102↓2.7% | -99↓48.6% | -67 | |
| EPS (Basic) | -1.59↑3.6% | -1.65↓19.6% | -1.38↑15.9% | -1.64↓47.7% | -1.11 | |
| EPS (Diluted) | -1.59↑3.6% | -1.65↓19.6% | -1.38↑15.9% | -1.64↓47.7% | -1.11 | |
| Weighted Average Shares | 93↑3.4% | 90↑22.4% | 74↑21.4% | 61↑0.9% | 60 | |
| Weighted Average Diluted Shares | 93↑3.4% | 90↑22.4% | 74↑21.4% | 61↑0.9% | 60 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.